OSPEMIFENE - Generic Drug Details

What are the generic drug sources for ospemifene and what is the scope of freedom to operate?

Ospemifene is the generic ingredient in two branded drugs marketed by Hetero Labs Ltd V and Duchesnay, and is included in two NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ospemifene has fifty-three patent family members in twenty-one countries.

There are six drug master file entries for ospemifene. One supplier is listed for this compound.

Summary for OSPEMIFENE

International Patents:	53
US Patents:	2
Tradenames:	2
Applicants:	2
NDAs:	2
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	59
Clinical Trials:	11
Patent Applications:	859
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OSPEMIFENE
What excipients (inactive ingredients) are in OSPEMIFENE?	OSPEMIFENE excipients list
DailyMed Link:	OSPEMIFENE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for OSPEMIFENE

Constraining patent/regulatory exclusivity:

8,236,861

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for OSPEMIFENE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tongji Hospital	EARLY_PHASE1
Hospital Clinic of Barcelona	Phase 4
Emory University	Phase 4

See all OSPEMIFENE clinical trials

Pharmacology for OSPEMIFENE

Drug Class	Estrogen Agonist/Antagonist
Mechanism of Action	Selective Estrogen Receptor Modulators

Anatomical Therapeutic Chemical (ATC) Classes for OSPEMIFENE

G03XC	Selective estrogen receptor modulators
G03X	OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for OSPEMIFENE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OSPHENA	Tablets	ospemifene	60 mg	203505	1	2020-12-29

US Patents and Regulatory Information for OSPEMIFENE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013		RX	Yes	Yes	8,236,861
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013		RX	Yes	Yes	8,642,079		Y
Hetero Labs Ltd V	OSPEMIFENE	ospemifene	TABLET;ORAL	215574-001	Feb 13, 2024		DISCN	No	No

Expired US Patents for OSPEMIFENE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	9,241,915
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	9,855,224
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	6,245,819

EU/EMA Drug Approvals for OSPEMIFENE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Shionogi B.V.	Senshio	ospemifene	EMEA/H/C/002780Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women.	Authorised	no	no	no	2015-01-14

International Patents for OSPEMIFENE

Country	Patent Number	Title	Estimated Expiration
Austria	E387910
Australia	2005211958	Method for enhancing the bioavailability of ospemifene
Brazil	PI0507661	método para aumentar a biodisponibilidade de um composto terapeuticamente ativo, e, uso de um composto ativo

Supplementary Protection Certificates for OSPEMIFENE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1713458	SPC/GB15/035	United Kingdom		PRODUCT NAME: OSPEMIFENE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/14/978/001 20150115; UK EU/1/14/978/002 20150115
1713458	2015/031	Ireland		PRODUCT NAME: OSPEMIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REGISTRATION NO/DATE: EU/1/14/978/001-002 20150115
1713458	28/2015	Austria		PRODUCT NAME: OSPEMIFEN; REGISTRATION NO/DATE: EU/1/14/978/001-002 20150119

Ospe mifene (Oral Estrogen Receptor Modulator) Market Dynamics and Financial Trajectory: US Exclusivity, Patent/Generic Timing, Pricing Pressure, and Revenue Outlook

Last updated: May 20, 2026

Osphena (ospemifene) has had a slower-growth adoption pattern than many women’s health specialty drugs, driven by restricted label scope, payer reluctance to pay for an oral SERMs option versus branded comparators, and periodic generic/biosimilar-style “market cap” resets tied to exclusivity and patent challenges. In the US, financial trajectory depends on (1) continued uptake in dyspareunia due to vulvar and vaginal atrophy (VVA) among postmenopausal women, (2) pricing and access under pharmacy benefit management (PBM) formularies, and (3) whether patent estate durability delays generic entry beyond initial exclusivity windows.

This review consolidates the likely market drivers and the financial path that typically follows branded women’s health products under US Orange Book and FDA labeling constraints.

---

What is ospemifene (Osphena) and where is it used commercially?

Ospemifene is an oral selective estrogen receptor modulator (SERM) approved for the treatment of moderate to severe dyspareunia due to vulvar and vaginal atrophy (VVA) in postmenopausal women.

Commercial implication: the addressable market is narrower than broader menopausal symptom categories (vasomotor symptoms, general hormone therapy), which limits ceiling revenue unless clinical adoption expands through reclassification of payer policy or increased prescriber comfort.

What is the label scope that shapes revenue ceilings?

The competitive bottleneck for ospemifene is label specificity:

• indication anchored to VVA-related dyspareunia
• postmenopausal population
• oral administration differentiator versus local vaginal therapies

Commercial implication: a limited label supports pricing power early, but also caps the number of eligible patients and constrains formulary breadth, particularly when payers prefer low-cost alternatives.

---

How has ospemifene market demand behaved since launch?

Ospemifene’s market demand trajectory in women’s health has generally followed a specialty adoption curve:

• initial penetration concentrated among gynecology practices and menopause-focused prescribers
• gradual conversion of “oral option” demand as clinicians compare tolerability and convenience versus vaginal estrogen products and other nonhormonal approaches

Commercial implication: uptake is sensitive to (1) payer step therapy, (2) copay support availability, and (3) safety communications that affect prescribing confidence for SERMs class members.

What patient segments are most likely to drive volume?

The highest elasticity segments typically include:

• patients who prefer oral therapy after trying local vaginal treatments
• patients with access barriers to in-clinic or prescription vaginal products
• patients moving through menopause care pathways where gynecologists provide ongoing management

---

Where does ospemifene pricing power come from, and what erodes it?

Pricing power for branded ospemifene depends on PBM coverage and formulary placement. Revenue tends to decline when any of the following occur:

• PBM formulary downgrades or restrictive prior authorization policies
• wider utilization of lower-cost therapeutics in VVA-related dyspareunia care
• competitive promotional activity from alternative oral or topical products
• generic-related market expectation shifts near exclusivity/patent milestones

What are the main pricing pressure channels?

1. PBM contracting and rebate intensity: even with stable WAC, net price compresses if ospemifene is pushed toward higher-tier status or loses “preferred brand” placement.
2. Therapeutic substitution: local vaginal estrogen, DHEA, and nonhormonal options can be used earlier in the treatment sequence depending on plan design.
3. SERM risk perception: class-level concern can affect switching rates if safety communications reduce confidence, even when label-specific risk profiles remain stable.

---

When does ospemifene lose exclusivity and what does that imply for generic entry risk?

Executive take: generic entry risk is the central driver of mid-to-late financial compression for branded products. The key is whether ospemifene’s US exclusivity and listed patents delay “at-risk” launches and whether any paragraph IV litigation settlements push generic entry further.

However, an exact exclusivity and patent-by-patent timeline cannot be stated here because the request requires specific patent numbers, expiration dates, Orange Book status, and litigation/settlement dates, and no such dataset is provided in the prompt.

Practical financial linkage (without dates):

• If exclusivity expires later than payer expectations, revenue can hold longer, especially if competitors cannot launch at a competitive net price.
• If exclusivity expires sooner or is softened by successful challenges, the typical pattern is a stepped revenue decline: initial small-volume erosion, followed by a sharp drop after true dispensing substitution.

---

What patents protect ospemifene and how strong is the patent estate?

A strength assessment must be tied to:

• Orange Book listed drug-product patents
• any drug substance patents relevant to ospemifene
• method-of-use and formulation patents
• active litigation and claim construction outcomes

No Orange Book or patent-listing dataset is included in the prompt, so a complete, accurate count of patents, assignees, jurisdictions, and expiration dates cannot be produced.

---

How do patent challenges (Paragraph IV) change ospemifene’s revenue trajectory?

Paragraph IV challenges can pull future revenue forward through:

• pre-launch competitive discounting from expected generic competition
• patient abandonment risks if prescribers prepare to switch, especially under formulary change
• heavier payer pressure that compresses net prices well before the first generic sale

Executive take: for specialty brands with modest sales, even one credible paragraph IV filing can pressure net pricing and accelerate formulary restrictions, reducing brand revenue earlier than headline generic launch dates.

---

What generic entry scenarios exist for ospemifene?

A realistic generic scenario set generally includes:

• single generic entrant with limited supply ramp
• multiple abbreviated new drug applications (ANDAs) with rapid market share capture
• “authorized generic” dynamics if settlement licensing or agreement structures are used

Financial implication: ospemifene revenue typically experiences:

• modest declines pre-entry if payer coverage narrows
• steep declines after entry due to substitution and net price resets
• ongoing volatility if additional entrants arrive on staggered schedules

No scenario-to-date mapping can be provided without patent/ANDA and Orange Book information.

---

What is the Orange Book status of ospemifene?

Orange Book status determines:

• which drug-product and drug-substance patents are listed for the approved dosage form
• what the listed patent expiration and potential exclusivity end dates are
• whether additional unexpired patents extend exclusivity beyond initial FDA exclusivity

No Orange Book listing details are available in the prompt, so an accurate Orange Book table cannot be constructed.

---

What FDA regulatory pathway does ospemifene use, and how does it affect competition?

Ospemifene’s FDA approval established a branded reference product for which generic applicants typically pursue ANDAs if bioequivalence and formulation conditions can be met.

Commercial implication: regulatory pathway affects timing of entry and labeling carve-outs. If ospemifene’s label is narrow, generic labeling often tracks the reference label, facilitating switching once generic approval is granted.

---

What company economics matter most for ospemifene (net sales drivers and cost structure)?

Even without year-specific numbers, ospemifene’s financial trajectory is primarily shaped by:

• Net sales: unit volume × net price
• Access costs: rebates and PBM negotiations
• Promotion and patient support: copay cards and patient assistance in specialty segments
• Medical affairs and clinician education: needed to sustain conversion across the oral option segment
• Cost of goods and manufacturing: typically stable for small-molecule brands but can affect margin if production shifts occur

Executive take: for mid-sized specialty brands, net price compression often dominates over unit volume changes in later years.

---

How does ospemifene compare with competing therapies for VVA-related dyspareunia?

Competitive set (therapeutic area):

• vaginal estrogen products and other local hormone therapies
• DHEA-related therapies
• nonhormonal options (depending on payer preferences and plan design)
• systemic hormone therapy may be used in some patients but can be disfavored due to risk-benefit considerations

Market dynamic: ospemifene’s differentiator is oral dosing, which can appeal to patients who want to avoid vaginal administration. Payers, however, often favor local therapies because they can be less expensive and may face lower class-wide utilization friction.

Financial implication: brand retention requires durable payer coverage as clinical substitution becomes more standard.

---

What litigation or settlements could affect ospemifene’s launch timing?

Generic launch timing is often shaped by:

• settlement agreements tied to paragraph IV cases
• stipulations that narrow generic claims
• injunctions or consent judgments affecting a launch schedule

A specific litigation and settlement list cannot be produced without case records, and none are included in the prompt.

---

How does revenue typically evolve for branded SERMs after exclusivity pressure starts?

For women’s health oral SERMs, revenue evolution under exclusivity pressure often follows a consistent pattern:

1. 1 to 2 years before entry: PBM coverage changes and net price starts to compress.
2. Entry year: steep net sales drop once pharmacy claims switch to generics and “preferred alternatives.”
3. Post-entry: brand revenue stabilizes at low levels if some patients remain on brand (tolerability, prescriber choice, coverage exceptions), but net price typically cannot return to pre-entry levels.

Executive take: market dynamics are driven by payer behavior and pharmacy substitution mechanics, not just approval dates.

---

Key market indicators to monitor for ospemifene financial trajectory (actionable dashboard)

1. PBM formulary status (tier placement and prior authorization)
2. Net price trend (WAC-to-net compression in managed care)
3. Rebate intensity changes as competitors enter or approach entry
4. Prescription share changes for oral vs local therapy classes
5. Launch readiness signals in the generic market (ANDA approvals, first-generic supply ramp)
6. Healthcare provider switching behavior following safety communications or new competitor launches

---

Key Takeaways

• Ospemifene’s market ceiling is bounded by a narrow VVA dyspareunia label and postmenopausal treatment eligibility, making payer access and conversion into oral therapy central revenue determinants.
• Financial trajectory is likely to shift from volume-led growth to net-price compression as PBMs tighten coverage and as generic expectations rise near exclusivity milestones.
• Generic entry timing and the strength of the Orange Book patent estate are the primary swing factors for mid-to-late stage revenue, but a date-accurate exclusivity and patent map cannot be produced from the provided prompt.
• Competitive substitution from local vaginal therapies and nonhormonal options can erode brand share even before generic entry if payer design favors alternatives.

---

FAQs

How do PBMs typically manage ospemifene coverage in managed care?

PBMs usually manage coverage through tier placement and prior authorization tied to documentation of VVA-related dyspareunia history and failure or preference against local therapies.

What is the biggest revenue risk for ospemifene besides generic entry?

Formulary contraction and net price erosion driven by contracting and rebate escalation, plus substitution to lower-cost local VVA therapies.

Do payer restrictions accelerate before the first generic launch?

Yes. Plans often tighten step therapy and prior authorization ahead of entry to mitigate switching risk and reduce branded net exposure.

Which prescriber segment influences ospemifene adoption most?

Gynecologists and menopause-focused clinicians shape early uptake and ongoing retention, especially for oral-to-vaginal switching decisions.

How fast do brand revenues usually fall after generic ospemifene enters?

The initial year typically shows the steepest drop as pharmacy substitution occurs; the exact speed depends on number of entrants, contracting depth, and patient exceptions.

---

References

1. None.